Hosted on MSN
AAD: Ixekizumab + tirzepatide boosts psoriatic arthritis outcomes more than ixekizumab monotherapy
MONDAY, April 6, 2026 (HealthDay News) -- Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits for outcomes in psoriatic arthritis (PsA) versus IXE alone in adults with overweight or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results